Amylin (AMLN) Announces BYETTA Approved As Stand-Alone Medication
Up)
Over the weekend, Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that the FDA has approved an expanded indication for BYETTA injection.
BYETTA is now approved for use as a stand-alone medication along with diet and exercise to improve glycemic control in adults with type 2 diabetes. Previously, it was approved for use only in patients who were also taking other common diabetes medications and had not achieved adequate glycemic control.
BYETTA is now approved for use as a stand-alone medication along with diet and exercise to improve glycemic control in adults with type 2 diabetes. Previously, it was approved for use only in patients who were also taking other common diabetes medications and had not achieved adequate glycemic control.
You May Also Be Interested In
- Boehringer Ingelheim, Lilly (LLY) Say Linagliptin Showed Significant Improvement in HbA1c in Phase 3
- American College of Endocrinology (ACE) and Lilly Diabetes Offer New Tips to Help People With Diabetes Prepare for Emergencies
- Perrigo (PRGO) Gets FDA Approval for Generic Gynazole 1
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
